AU2007209581B2 - FGF2-binding peptides and uses thereof - Google Patents

FGF2-binding peptides and uses thereof Download PDF

Info

Publication number
AU2007209581B2
AU2007209581B2 AU2007209581A AU2007209581A AU2007209581B2 AU 2007209581 B2 AU2007209581 B2 AU 2007209581B2 AU 2007209581 A AU2007209581 A AU 2007209581A AU 2007209581 A AU2007209581 A AU 2007209581A AU 2007209581 B2 AU2007209581 B2 AU 2007209581B2
Authority
AU
Australia
Prior art keywords
ptx3
fgf2
peptide
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007209581A
Other languages
English (en)
Other versions
AU2007209581A1 (en
Inventor
Maura Camozzi
Maurizio Colombo
Domenico Mastroianni
Marco Presta
Marco Rusnati
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU2007209581A1 publication Critical patent/AU2007209581A1/en
Assigned to SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. reassignment SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. Request for Assignment Assignors: TECNOGEN S.P.A.
Application granted granted Critical
Publication of AU2007209581B2 publication Critical patent/AU2007209581B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
AU2007209581A 2006-01-24 2007-01-23 FGF2-binding peptides and uses thereof Ceased AU2007209581B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06001457.8 2006-01-24
EP06001457 2006-01-24
PCT/EP2007/000538 WO2007085412A1 (en) 2006-01-24 2007-01-23 Fgf2-binding peptides and uses thereof

Publications (2)

Publication Number Publication Date
AU2007209581A1 AU2007209581A1 (en) 2007-08-02
AU2007209581B2 true AU2007209581B2 (en) 2013-03-28

Family

ID=37421191

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007209581A Ceased AU2007209581B2 (en) 2006-01-24 2007-01-23 FGF2-binding peptides and uses thereof

Country Status (19)

Country Link
US (1) US8076300B2 (https=)
EP (1) EP1973944B1 (https=)
JP (1) JP5427415B2 (https=)
KR (1) KR101467453B1 (https=)
CN (1) CN101384622B (https=)
AU (1) AU2007209581B2 (https=)
BR (1) BRPI0707239A8 (https=)
CA (1) CA2637295C (https=)
DK (1) DK1973944T3 (https=)
EA (1) EA015339B1 (https=)
ES (1) ES2575517T3 (https=)
HR (1) HRP20160600T1 (https=)
HU (1) HUE029212T2 (https=)
IL (1) IL192800A (https=)
MX (1) MX2008009289A (https=)
PL (1) PL1973944T3 (https=)
PT (1) PT1973944T (https=)
SI (1) SI1973944T1 (https=)
WO (1) WO2007085412A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204928A1 (en) * 2017-05-05 2018-11-08 Board Of Regents, The University Of Texas System Fgl2 monoclonal antibodies and their use in treating malignant tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032516A2 (en) * 1997-12-19 1999-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical compositions containing the long pentraxin ptx3
WO2003072603A2 (en) * 2002-02-28 2003-09-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317930B1 (it) * 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999032516A2 (en) * 1997-12-19 1999-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pharmaceutical compositions containing the long pentraxin ptx3
WO2003072603A2 (en) * 2002-02-28 2003-09-04 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rusnati, M. et al., Blood 2004, vol. 104, pages 92-99 *

Also Published As

Publication number Publication date
CN101384622B (zh) 2013-03-27
IL192800A (en) 2015-04-30
DK1973944T3 (en) 2016-06-27
IL192800A0 (en) 2009-02-11
WO2007085412B1 (en) 2007-10-11
ES2575517T3 (es) 2016-06-29
MX2008009289A (es) 2008-10-17
EA015339B1 (ru) 2011-06-30
HUE029212T2 (en) 2017-02-28
US8076300B2 (en) 2011-12-13
CA2637295C (en) 2017-06-13
CA2637295A1 (en) 2007-08-02
BRPI0707239A8 (pt) 2018-01-30
SI1973944T1 (sl) 2016-07-29
EP1973944B1 (en) 2016-05-11
JP2009523457A (ja) 2009-06-25
JP5427415B2 (ja) 2014-02-26
KR101467453B1 (ko) 2014-12-01
CN101384622A (zh) 2009-03-11
WO2007085412A1 (en) 2007-08-02
US20090215689A1 (en) 2009-08-27
PT1973944T (pt) 2016-07-07
KR20080096794A (ko) 2008-11-03
EA200870188A1 (ru) 2009-02-27
AU2007209581A1 (en) 2007-08-02
BRPI0707239A2 (pt) 2011-04-26
PL1973944T3 (pl) 2016-09-30
HRP20160600T1 (hr) 2016-07-01
EP1973944A1 (en) 2008-10-01

Similar Documents

Publication Publication Date Title
JP4949844B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
KR102258864B1 (ko) 허혈성 손상 치료 및 예방용 조성물
DK2498799T3 (en) Use of the FGFR1 ECD proteins for the treatment of cancer diseases characterized by ligand dependent activating mutations in FGFR2
US9611306B2 (en) TGFB type II-type III receptor fusions
DK2437773T3 (en) PROCEDURE FOR IMPROVING PHAGOCYTOSIS OF PHOSPHATIDYLSERINE-EXPOSING CELLS
CA3000697A1 (en) Treatment of bile acid disorders
KR20070008510A (ko) 케모킨 변이체의 치료적 용도
KR20040101426A (ko) 신규한 ｍｃｐ 단백질의 길항제
AU2007209581B2 (en) FGF2-binding peptides and uses thereof
KR19990022716A (ko) 골 자극 인자
JP2008013436A (ja) 血管形成促進剤
KR100641535B1 (ko) 브이이지에프 펩티드 및 그 용도
CN107325187B (zh) 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物
AU2008256550B2 (en) VEGF-D mutants and their use
US20170166624A1 (en) TGFß TYPE II-TYPE III RECEPTOR FUSIONS
JP5034005B2 (ja) 細胞死誘導ペプチド、ｍａｐ化細胞死誘導ペプチド、細胞死誘導剤及び抗癌剤

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.

Free format text: FORMER APPLICANT(S): TECNOGEN S.P.A.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired